Tamoxifen is an antiestrogen drug with concentration dependent properties, with z-endoxifen known as active metabolite. Until know therapeutic range for z-endoxifen to improve treatment response was not known. Variation response on tamoxifen can be cause of genetic polymorphism CYP2D6 that can be different between interindividul and ethnic.
The aim of this study is to determine phenotype and genotype of CYP2D6 as predictors of z-endoxifen concentrations in plasma of outgoing patients treated with tamoxifen for at least 4 months
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Breast cancer patients on tamoxifen treatment for at least 4 months
You may not be if
Abnormalities in liver markers (AST \>2.5 x ULN)
Clareo Health | Genotyping and Phenotyping of CYP2D6 Breast Cancer Patients on Tamoxifen
